Voyager Therapeutics Stock Forum

$Voyager Therapeutics(VYGR.US)$ Voyager Therapeutics To Present Translational Data For IV-Delivered, CNS Gene Therapy Programs Advancing Toward Clinical Trials At ASGCT 27th Annual Meeting

$Voyager Therapeutics(VYGR.US)$ Voyager Therapeutics And Neurocrine Biosciences Have Selected Lead Development Candidate In GBA1 Gene Therapy Program For Potential Treatment Of Parkinson's Disease And Other GBA1-mediated Diseases.                                       Triggers 3 million milestone payment

$Voyager Therapeutics(VYGR.US)$ buy the low

$Voyager Therapeutics(VYGR.US)$ 🐂looks good

RECAP
Stocks declined for a second day, weighed down by declines in tech giants that previously lifted major indices higher in 2023.
The tech-heavy $Nasdaq Composite Index(.IXIC.US)$ lost 1.2% to 14,592.21, building on its worst daily performance since October. The $S&P 500 Index(.SPX.US)$ declined 0.8% to 4,704.81, while the $Dow Jones Industrial Average(.DJI.US)$ fell 0.8% to 37,430.19.
Software stocks tracked by moomoo slid...

$Voyager Therapeutics(VYGR.US)$ climbed 19% Wednesday, extending this week's rally that was fueled by the company's recent license pact with a unit of Novartis AG.
On Tuesday, Voyager shares surged as much as 39% after the company said it will receive $100 million up front as part of a license pact with Novartis that includes a $20 million purchase of newly issued equity in Voyager. Voyager will also be eligible to get as much as $...

$Voyager Therapeutics(VYGR.US)$ Under the deal's terms, Voyager will receive $100 million up front, including $20 million in equity, and up to $1.2 billion in milestone payments. Voyager is also eligible to receive tiered royalties on sales of new drugs that use its technology.